N-valeryl-phenylalanine | 16859-51-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-valeryl-phenylalanine
• 英文别名: N-Valeryl-phenylalanin；2-Pentanamido-3-phenylpropanoic acid；2-(pentanoylamino)-3-phenylpropanoic acid
• CAS: 16859-51-1；54897-04-0
• 化学式: C₁₄H₁₉NO₃
• mdl: MFCD09811748
• 分子量: 249.31
• InChiKey: YXQLJEQFZUMUPB-UHFFFAOYSA-N

物化性质

• 沸点：
  473.1±38.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  DL-苯丙氨酸 、 戊酰氯 在 吡啶 作用下， 生成 N-valeryl-phenylalanine
  参考文献：
  名称：

  Carter; Handler; Stevens, Journal of Biological Chemistry, 1941, vol. 138, p. 619,621

  摘要：

  DOI：

文献信息

• Flavour Modifying Compounds
  申请人：Givaudan S. A.

  公开号：US20140127144A1

  公开（公告）日：2014-05-08

  A compound of formula (I) is used to modify the taste or flavour of a flavour composition or consumable product, wherein R 1 is H, or a substituted, unsubstituted, branched or unbranched C 1 -C 5 alkyl group and, NHR 2 is a residue of an amino acid, is selected from Alanine (Ala), cysteine (Cys), Aspartic acid (Asp), phenylalanine (Phe), glutamic acid (Glu), histidine (His), isoleucine (Ile), lysine (Lys), leucine (Leu), methionine (Met), asparagines (Asn), glutamine (Gln), arginine (Arg), serine (Ser), theronine (Thr), valine (Val), tryptophan (Trp), tyrosine(Tyr) and Glycine (Gly), with the proviso that the compound is not N-acetyl glycine. Also disclosed are flavour compositions and consumable products containing such compounds.

  化合物的化学式（I）用于改变风味组合物或可食用产品的味道或风味，其中R1是H，或者是取代的、未取代的、支链的或非支链的C1-C5烷基基团，NHR2是氨基酸残基，选自丙氨酸（Ala）、半胱氨酸（Cys）、天冬氨酸（Asp）、苯丙氨酸（Phe）、谷氨酸（Glu）、组氨酸（His）、异亮氨酸（Ile）、赖氨酸（Lys）、亮氨酸（Leu）、蛋氨酸（Met）、天冬酰胺（Asn）、谷氨酰胺（Gln）、精氨酸（Arg）、丝氨酸（Ser）、苏氨酸（Thr）、缬氨酸（Val）、色氨酸（Trp）、酪氨酸（Tyr）和甘氨酸（Gly），但该化合物不是N-乙酰甘氨酸。还公开了含有这种化合物的风味组合物和可食用产品。
• [EN] A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE SITAGLIPTINE
  申请人：SMILAX LAB LTD

  公开号：WO2013114173A1

  公开（公告）日：2013-08-08

  The present invention is directed to a process for the preparation of enantiomerically enriched β-amino acid derivatives which are important chiral building blocks and intermediates in pharmaceuticals. More specifically, the invention pertains to a novel process for practically convenient and economically producing enantiomerically enriched β-amino acid derivatives which are useful for the synthesis of amide inhibitors of dipeptidyl peptidase IV like Sitagliptin, which have been used to treat type 2 diabetes.

  本发明涉及一种制备对映富集的β-氨基酸衍生物的方法，这些衍生物是重要的手性构建块和药物中间体。更具体地，该发明涉及一种新颖的方法，用于方便实用和经济地生产对映富集的β-氨基酸衍生物，这些衍生物对于合成类似西他列汀的二肽基肽酶IV抑制剂的酰胺具有用处，这些抑制剂已被用于治疗2型糖尿病。
• Composition containing a penem or carbapenem antibiotic
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0178911A2

  公开（公告）日：1986-04-23

  57 Administration of an N-acylated amino acid (ornithine, lysine, phenylglycine or phenylalanine) in association with a penem or carbapenem antibiotic relieves or eliminates the renal problems associated with administration of the antibiotic alone. The amino acid and antibiotic may be formulated together as a composition or administered separately, either simultaneously or sequentially. A pharmaceutical composition may be prepared simply by mixing the two components.

  57 将 N-酰化氨基酸（鸟氨酸、赖氨酸、苯甘氨酸或苯丙氨酸）与培南类或碳青霉烯类抗生素联合给药，可缓解或消除与单独给药抗生素相关的肾脏问题。 氨基酸和抗生素可一起配制成组合物，也可同时或依次单独给药。 只需将两种成分混合即可制备成药物组合物。
• Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
  申请人：Metabolon, Inc.

  公开号：US10267777B2

  公开（公告）日：2019-04-23

  Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

  本文描述了对个体受试者进行小分子生化分析的方法，以诊断疾病或失调，促进疾病或失调的诊断，和/或确定个体受试者罹患疾病或失调的风险增加。确定个体受试者样本中存在的小分子的异常水平，并根据确定的异常水平获得与个体受试者相关的诊断信息。所获得的诊断信息包括：至少一个生化途径的鉴定，该生化途径与所鉴定的具有异常水平的小分子子集相关；至少一种疾病或紊乱的鉴定，该疾病或紊乱与所鉴定的具有异常水平的小分子子集相关；至少一种推荐的后续检测的鉴定，该检测与所鉴定的具有异常水平的小分子子集相关。
• FLAVOUR MODIFYING COMPOUNDS
  申请人：Givaudan SA

  公开号：EP2731453A1

  公开（公告）日：2014-05-21